Crinetics Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Crinetics Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRNX

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. 

CEO
Scott R. Struthers
CEOScott R. Struthers
Employees
437
Employees437
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2008
Founded2008
Employees
437
Employees437

CRNX Key Statistics

Market cap
4.68B
Market cap4.68B
Price-Earnings ratio
-10.88
Price-Earnings ratio-10.88
Dividend yield
Dividend yield
Average volume
1.02M
Average volume1.02M
High today
$50.93
High today$50.93
Low today
$48.75
Low today$48.75
Open price
$50.67
Open price$50.67
Volume
1.15M
Volume1.15M
52 Week high
$56.15
52 Week high$56.15
52 Week low
$24.10
52 Week low$24.10

Stock Snapshot

The current Crinetics Pharmaceuticals(CRNX) stock price is $49.32, with a market capitalization of 4.68B. The stock trades at a price-to-earnings (P/E) ratio of -10.88.

As of 2025-12-16, Crinetics Pharmaceuticals(CRNX) stock has fluctuated between $48.75 and $50.93. The current price stands at $49.32, placing the stock +1.2% above today's low and -3.2% off the high.

Crinetics Pharmaceuticals(CRNX) shares are trading with a volume of 1.15M, against a daily average of 1.02M.

During the past year, Crinetics Pharmaceuticals(CRNX) stock moved between $24.10 at its lowest and $56.15 at its peak.

During the past year, Crinetics Pharmaceuticals(CRNX) stock moved between $24.10 at its lowest and $56.15 at its peak.

CRNX News

Simply Wall St 4d
Crinetics Pharmaceuticals Valuation Check After First-Patient Dosing in New SST2 Tumor Trial

Crinetics Pharmaceuticals (CRNX) just hit an important milestone, as it has dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for SST2 positi...

Crinetics Pharmaceuticals Valuation Check After First-Patient Dosing in New SST2 Tumor Trial

Analyst ratings

88%

of 16 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own CRNX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.